24th Jan 2014 10:50
LONDON (Alliance News) - Pharmaceuticals giant GlaxoSmithKline PLC said Friday that it had received a recommendation for marketing authorisation for its Eperzan treatment for type 2 diabetes from the European Medicines Agency's Committee for Medical Products for Human Use.
The recommendation is for the use of Eperzan as a once-weekly treatment in adult patients with type 2 diabetes when diet and exercise alone do not provide adequate control, and as an add-on combination therapy with other glucose-lowering medicinal products.
Friday's approval is one of the penultimate steps towards marketing authorisation from the European Commission. Glaxo expects a decision on marketing authorisation during the first quarter of 2014.
Shares in Glaxo were trading down 0.4% at 1,645.59 pence Friday.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline